Fast, actionable treatment decisions for NSCLC patients
ASPYRE®-Lung is the first clinical application for ASPYRE®, a new category of rapid, comprehensive biomarker testing. It was specifically created to provide physicians with actionable results within days of diagnosis, enabling rapid identification of the best treatment options.
Fast time to treatment
ASPYRE is a patented molecular chemistry that uses a unique enzymatic reaction to dramatically accelerate the detection of actionable biomarkers from tissue or blood within hours vs. weeks for sequencing technologies.
ASPYRE is as sensitive and specific as gold standard NGS assays, For DNA: 100% positive and negative percent agreement: For RNA: 100% positive and negative percent agreement.
Reduced sample requirement
ASPYRE’s high sensitivity enables testing from tissue samples with as little as 10% tumor content, as compared to 20% to 30% for most competing assays, minimizing the frustration from not having enough sample to run the assay (QNS) or failure rates for sequencing technologies (QC).
ASPYRE-Lung comprehensive lung panel includes all NCCN guideline recommended genomic biomarkers associated with targeted therapies for NSCLC.
DNA + RNA
ASPYRE-Lung simultaneously analyzes DNA and RNA from blood or tissue in a single assay, maximizing the opportunity to identify mutations and fusions, while avoiding the additional time and expense of running separate assays.
At a fraction of the cost of NGS, ASPYRE was created to increase patient access to biomarker testing, and to minimize the barrier of prior authorization from payors.
Biomarkers included in ASPYRE-Lung
ASPYRE-Lung enables the simultaneous analysis of 77 DNA mutations & 37 RNA fusions.